Nuvance (Immunex).
Immunex is carrying out worldwide phase II trials on a genetically-engineered soluble interleukin-4 receptor (IL-4R, Nuvance), administered as a nebulized liquid, for the potential treatment of allergic asthma. IL-4R may also be of use in the treatment of organ transplant rejection, graft versus host disease, allergy and infectious disease.